Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Adaptive Bio, BMS In Biomarker Discovery Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Adaptive Bio, BMS In Biomarker Discovery Pact

Will use immune assay to identify biomarkers in cells of cancer patients

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Adaptive Biotechnologies has entered into a collaboration with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology. Adaptive will use its immune profiling assay, immunoSEQ, to identify potential biomarkers in cells of cancer patients to assess the impact of treatments on the immune system and to identify patient populations more likely to respond to targeted therapies. The assay uses high throughput next-gen sequencing to characterize T and B cell receptors. 
 
“We are delighted to collaborate with Bristol-Myers Squibb to help uncover immunological biomarkers of response to cancer agents,” said Chad Robins, chief executive officer and Founder of Adaptive Biotechnologies. “Collaborating with Bristol-Myers Squibb is a real win for companies like ours that are committed to deepening the understanding of the interaction between the host immune system and the cancer cells themselves.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics